Ticagrelor

Apr 27, 2020

Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer

Apr 20, 2020

Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

Jan 29, 2020

CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

Oct 04, 2019

CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

Oct 02, 2019

CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

Sep 26, 2019

Aspirin Continues to be the Gold Standard Treatment for Millions of Americans Who Have Had a Cardiovascular Event

Sep 26, 2019

Coronary Stent Patients May Not Need Long-Term Aspirin - Mount Sinai

Sep 05, 2019

Spartan Bioscience Announces Publication of Landmark POPular Genetics Clinical Trial in the New England Journal of Medicine

Jun 07, 2017

Aralez Announces National U.S. Commercial Launch Of Zontivity